GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...
葛兰素史克(GSK.US)同意支付22亿美元以解决约8万起胃灼热药物Zantac ...
智通财经获悉，葛兰素史克(GSK.US)周三宣布，该公司已同意支付高达22亿美元，以解决美国州法院提起的大多数诉讼，这些诉讼指控一种已停产的胃灼热药物Zantac会导致癌症。该公司说，与10家原告律师事务所达成的协议解决了约8万起案件，占美国全国州法 ...
GSK将支付高达22亿美元解决Zantac诉讼案
领先的制药公司GSK plc (NYSE:GSK)今天宣布达成和解,以解决美国州法院大多数未决的Zantac(雷尼替丁)产品责任案件。该公司将支付高达22亿美元来解决约8万起案件,占针对该公司索赔的93%。此外,GSK原则上同意以7000万美元和解Valisure提起的qui tam诉讼。 这些和解并不意味着GSK承认任何责任,预计将在2025年上半年末前全面实施。GSK坚持认为,没有确凿的科学证 ...
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands ...
GSK settles vast majority of Zantac claims for $2.2 billion
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...
WJET Erie on MSN4 天
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
阿思達克財經網5 天
葛兰素史克(GSK.US)同意支付22亿美元以解决约8万起胃灼热药物Zantac ...
Zantac于1983年首次获得美国监管机构的批准，并于1988年成为世界上最畅销的药物，也是首批年销售额超过10亿美元的药物之一。这种药物在不同时期由 ...
GlaxoSmithKline股票前景因美国Arexvy销售不及预期而被修正 - 杰富瑞证券
周四，全球投资银行杰富瑞证券调整了GlaxoSmithKline (GSK:LN) (NYSE: GSK)的股票目标价，将其从之前的21.00英镑下调至20.00英镑。尽管如此，该公司仍维持对这家制药公司股票的"买入"评级。 此次修正是因为分析师预计GlaxoSmithKline第三季度的销售和利润可能低于市场预期，主要原因是美国Arexvy的表现不如预期。然而，分析师指出，该公司预计将重申其20 ...